Fusion of metabolic function and morphology:: Sequential [18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer

被引:115
作者
Du, Yong
Cullum, Ian
Illidge, Tim M.
Ell, Peter J.
机构
[1] UCL Hosp, Inst Nucl Med, Natl Hlth Serv Fdn, London NW1 2BU, England
[2] UCL, London, England
[3] Univ Manchester, Canc & Imaging Sch, Manchester, Lancs, England
[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
关键词
D O I
10.1200/JCO.2007.11.2854
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose By monitoring bone metastases with sequential [F-18] fluorodeoxyglucose positron-emission tomography/ computed tomography ([F-18] FDG-PET/CT) imaging, this study investigates the clinical relevance of [F-18] FDG uptake features of bone metastases with various radiographic appearances. Patients and Methods Bone metastases were found in 67 of 408 consecutive patients with known/ suspected recurrent breast cancer on [F-18] FDG- PET/CT, characterized by CT morphology changes and/ or bony [F-18] FDG uptake. Twenty-five of the patients had sequential [F-18] FDG- PET/ CT examinations ( 86 studies) over an average follow- up period of 23 months. The temporal changes in [F-18] FDG uptake and corresponding CT morphology features of 146 bone lesions identified in these 25 patients were followed up and correlated with therapeutic outcome retrospectively. Results The 146 lesions were classified as osteolytic (77), osteoblastic (41), mixed-pattern (11), or no change/ negative ( 17) on CT. The majority of the osteolytic (72; 93.5%) and mixed- pattern lesions ( nine; 81.8%), but fewer of the osteoblastic lesions (25; 61%), showed increased [F-18] FDG uptake. After treatment, 58 osteolytic lesions ( 0.5%) became [F-18] FDG negative and osteoblastic on CT and only 14 relatively large lesions (19.5%) remained [F-18] FDG avid. Of the 25 [F-18] FDG-avid osteoblastic lesions, 13 (52%) became [F-18] FDG negative, but 12 (48%) remained [F-18] FDG avid and increased in size on CT. Five of the mixed-pattern lesions remained [F-18] FDG avid after treatment. All 17 CT-negative lesions became [F-18] FDG negative; however, nine of them became osteoblastic. None of the initially [F-18] FDG-negative lesions showed [F-18] FDG avidity during follow-up. Conclusion [F-18] FDG uptake reflects the immediate tumor activity of bone metastases, whereas the radiographic morphology changes vary greatly with time among patients.
引用
收藏
页码:3440 / 3447
页数:8
相关论文
共 40 条
[1]   Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer [J].
Abe, K ;
Sasaki, M ;
Kuwabara, Y ;
Koga, H ;
Baba, S ;
Hayashi, K ;
Takahashi, N ;
Honda, H .
ANNALS OF NUCLEAR MEDICINE, 2005, 19 (07) :573-579
[2]   False negative F-18FDG PET/CT in nonsmall cell lung cancer bone metastases [J].
An, YS ;
Yoon, DK ;
Lee, MH ;
Joh, CW ;
Yoon, SN .
CLINICAL NUCLEAR MEDICINE, 2005, 30 (03) :203-204
[3]   Statistics notes - Survival probabilities (the Kaplan-Meier method) [J].
Bland, JM ;
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7172) :1572-1572
[4]   The logrank test [J].
Bland, JM ;
Altman, DG .
BRITISH MEDICAL JOURNAL, 2004, 328 (7447) :1073-1073
[5]  
Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5-6-463
[6]   Detection of bone metastases in breast cancer by 18FDG PET:: Differing metabolic activity in osteoblastic and osteolytic lesions [J].
Cook, GJ ;
Houston, S ;
Rubens, R ;
Maisey, MN ;
Fogelman, I .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3375-3379
[7]   Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].
Croucher, PI ;
Shipman, CM ;
Lippitt, J ;
Perry, M ;
Asosingh, K ;
Hijzen, A ;
Brabbs, AC ;
van Beek, EJR ;
Holen, I ;
Skerry, TM ;
Dunstan, CR ;
Russell, GR ;
Van Camp, B ;
Vanderkerken, K .
BLOOD, 2001, 98 (13) :3534-3540
[8]   The contribution of PET/CT to improved patient management [J].
Ell, PJ .
BRITISH JOURNAL OF RADIOLOGY, 2006, 79 (937) :32-36
[9]   Osteoblastic bone metastases in breast cancer: is not seeing believing? [J].
Fogelman, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (11) :1250-1252
[10]   Positron emission tomography and bone metastases [J].
Fogelman, I ;
Cook, G ;
Israel, O ;
Van der Wall, H .
SEMINARS IN NUCLEAR MEDICINE, 2005, 35 (02) :135-142